Intrauterine G-CSF Administration in RIF (G-CSF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03783208|
Recruitment Status : Completed
First Posted : December 20, 2018
Last Update Posted : December 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: G-CSF Other: Saline||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||157 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Intrauterine G-CSF Administration in Recurrent Implantation Failure|
|Actual Study Start Date :||November 1, 2018|
|Actual Primary Completion Date :||December 20, 2018|
|Actual Study Completion Date :||December 20, 2018|
Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
Other Name: Leucostim
Placebo Comparator: Control group
Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
- Clinical pregnancy rate [ Time Frame: 1month ]Gestational sac in USG per embryo transfer
- Endometrial thickness [ Time Frame: 1month ]Measurement of endometrial thickness as millimeter
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03783208
|Gurgan Clinic IVF and Women Health Center|
|Ankara, Cankaya, Turkey, 06640|
|Principal Investigator:||Ziya Kalem, MD||Gurgan Clinic IVF and Women Health Center|